Alzinova (ALZ) Q3 2024 earnings summary

Executive summary

• Alzinova focuses on developing disease-modifying treatments for Alzheimer's, with lead candidate ALZ-101 in late-stage phase 1b clinical trials and ALZ-201 in preclinical development.

• The company completed dosing in the high-dose part of the phase 1b study and expects long-term data by year-end 2024, with phase 2 preparations underway.

• Tord Labuda was appointed CEO as of October 1, 2024, following an interim period led by Carol Routledge.

Financial highlights

• Net sales were 0 TSEK for Q3 2024 (unchanged year-over-year); for the nine months, net sales reached 30 TSEK (0 TSEK prior year).

• Net loss after financial items was -4,151 TSEK for Q3 2024 (vs. -3,549 TSEK prior year); for the nine months, net loss was -13,990 TSEK (vs. -11,749 TSEK prior year).

• Total costs in Q3 2024 were 9,840 TSEK, with R&D expenses at 5,771 TSEK.

• Cash flow from operations in Q3 was 22,688 TSEK, boosted by a completed rights issue that raised 30.5 MSEK.

• Cash and cash equivalents at period end were 27,674 TSEK (32,905 TSEK prior year).

Outlook and guidance

• Long-term data from the phase 1b extension study are expected by year-end 2024; high-dose cohort data are anticipated early 2025.

• Preparations for phase 2 clinical trials are ongoing, including protocol development, drug manufacturing, and CRO selection.

• The company is actively pursuing strategic partnerships and evaluating financing options to support further development.